| Literature DB >> 28832799 |
Ernesto Koehler Chavez1, Alexandre Siciliano Colafranceschi1, Andrey José de Oliveira Monteiro1, Leonardo Secchin Canale1, Evandro Tinoco Mesquita2, Clara Weksler1, Odilon Nogueira Barbosa1, Anderson Oliveira2.
Abstract
OBJECTIVE: : To assess heart rhythm and predictive factors associated with sinus rhythm after one year in patients with rheumatic valve disease undergoing concomitant surgical treatment of atrial fibrillation. Operative mortality, survival and occurrence of stroke after one year were also evaluated.Entities:
Mesh:
Year: 2017 PMID: 28832799 PMCID: PMC5570393 DOI: 10.21470/1678-9741-2017-0016
Source DB: PubMed Journal: Braz J Cardiovasc Surg ISSN: 0102-7638
Fig. 1Atrial fibrillation (Reentry circuits). Adapted from Cox et al.[.
Fig. 2Lines of tissue lesion by radiofrequency in the left atrium. Adapted from Weimar et al. [.
Characteristics of the patients studied.
| Age (years) | |
|---|---|
| Minimum | 23 |
| Maximum | 72 |
| Mean ± SD | 50.76±10.7 |
| Gender | |
| Female | 78 (76%) |
| Male | 25 (24%) |
| SAH | 42 (40.7%) |
| DM | 8 (7.7%) |
| COPD | 21 (20.3%) |
| Previous stroke | 11 (10.5%) |
| Preoperative definitive pacemaker | 1 (0.1%) |
| Class 1 | 16 (15.5%) |
| Class 2 | 63 (61.5%) |
| Class 3 | 17 (18%) |
| Class 4 | 7 (5%) |
| EuroSCORE (mean ± SD) | 4.99±2.06 |
| Paroxysmal | 13 (12%) |
| Persistent | 8 (8%) |
| Permanent | 82 (80%) |
| Previous AF time ( mean ± SD ) | 39.9±4.68 months |
| Left atrial size ( mean ± SD ) | 5.6±0.8 cm |
| LV ejection fraction ( mean ± SD ) | 58.34%±11.65 (Teichholtz ) |
| Oral anticoagulant | 39.5% |
| LMWH | 18.6% |
| Beta-blockers | 27.8% |
| Digitalis | 23.2% |
| Antiarrhythmics | 6.9% |
| Diuretics | 65% |
| ACE inhibtor | 23% |
| ARBs | 6.9% |
NYHA=New York Heart Association; AF=atrial fibrillation; LV=left ventricle; cm=centimeter; LMWH = low molecular weight heparin; ACE = angiotensin-converting enzyme; ARBs = angiotensin receptor blockers
Fig. 3Types of surgeries performed.
mec MVR=mechanical mitral valve replacement; De Vega= Tricuspid repair using De Vega technique; bio MVR=Biological mitral valve replacement; TR ring=Tricuspid repair with ring; MR ring=Mitral repair with ring; TR=Tricuspid repair
Perioperative data.
| CPB time (min) | 125.47±30.52 |
|---|---|
| Myocardial ischemia time (min) | 105.85±28.34 |
| Type of ablation | |
| Unipolar | 20.19% |
| Bipolar | 79.81% |
CPB=cardiopulmonary bypass; Min=minutes
Fig. 4Ablation lines performed. Results expressed in absolute numbers.
R=right; L=left; LA=left atrium
Fig. 5Actuarial curve for event-free survival (stroke and death).
Fig. 6Cardiac rate at discharge and at the end of the 1-year postoperative follow-up period.
Fig. 7Actuarial curve for AF-free survival.
Multivariate analysis for sinus rhythm reversion one year after surgery.
| Variables in the model | β | Standardized coefficient | 95% Confidence Interval for the Settlement Ratio (SR) | |
|---|---|---|---|---|
| Lower limit | SR | Upper limit | ||
| Constant | 6.758 | |||
| Sinus rhythm on discharge | -3.381 | 0.08 | 0.034 | 0.142 |
| Size of the left atrium | -0.840 | 0.209 | 0.432 | 0.803 |
| Type of ablation | -2.079 | 0.032 | 0.125 | 0.483 |
Unipolar and Bipolar. R squared=0.494;
P<0.001;
P=0.003;
P = 0.024.
| Abbreviations, acronyms & symbols | |
|---|---|
| AF | = Atrial fibrillation |
| AHA | = American Heart Association |
| COPD | = Chronic obstructive pulmonary disease |
| CPB | = Cardiopulmonary bypass |
| LA | = Left atrium |
| LV | = Left ventricular |
| NYHA | = New York Heart Association Functional |
| SAH | = Systemic arterial hypertension |
| Authors' roles & responsibilities | |
|---|---|
| EKC | Substantial contributions to the conception or design of the work; or acquisition; final approval of the version to be published |
| ASC | Substantial contributions to the conception or design of the work; or acquisition; final approval of the version to be published |
| AJOM | Substantial contributions to the conception or design of the work; or acquisition; final approval of the version to be published |
| LSC | Substantial contributions to the conception or design of the work; or acquisition; final approval of the version to be published |
| ETM | Substantial contributions to the conception or design of the work; or acquisition; final approval of the version to be published |
| CW | Substantial contributions to the conception or design of the work; or acquisition; final approval of the version to be published |
| ONB | Substantial contributions to the conception or design of the work; or acquisition; final approval of the version to be published |
| AO | Substantial contributions to the conception or design of the work; or acquisition; final approval of the version to be published |